These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Prospects for combining immune checkpoint blockade with PARP inhibition. Li A; Yi M; Qin S; Chu Q; Luo S; Wu K J Hematol Oncol; 2019 Sep; 12(1):98. PubMed ID: 31521196 [TBL] [Abstract][Full Text] [Related]
43. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics. Li N; Wang Y; Deng W; Lin SH Anticancer Agents Med Chem; 2019; 19(2):206-212. PubMed ID: 30417796 [TBL] [Abstract][Full Text] [Related]
44. Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review. Xiong J; Barayan R; Louie AV; Lok BH Semin Cancer Biol; 2022 Nov; 86(Pt 2):521-542. PubMed ID: 35917883 [TBL] [Abstract][Full Text] [Related]
45. Epigenetic basis for PARP mutagenesis in glioblastoma: A review. M A; Xavier J; A S F; Bisht P; Murti K; Ravichandiran V; Kumar N Eur J Pharmacol; 2023 Jan; 938():175424. PubMed ID: 36442619 [TBL] [Abstract][Full Text] [Related]
46. [Abnormalities of DNA repair and gynecological cancers]. Auguste A; Leary A Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544 [TBL] [Abstract][Full Text] [Related]
47. HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer. Ma H; Qi G; Han F; Lu W; Peng J; Li R; Yan S; Yuan C; Kong B Cell Death Dis; 2022 Mar; 13(3):263. PubMed ID: 35332131 [TBL] [Abstract][Full Text] [Related]
48. Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis: Mechanism and Potential Role for PARP Inhibitors. Kotsopoulos IC; Kucukmetin A; Mukhopadhyay A; Lunec J; Curtin NJ Int J Gynecol Cancer; 2016 May; 26(4):763-9. PubMed ID: 26905326 [TBL] [Abstract][Full Text] [Related]
49. Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors. Jdey W; Thierry S; Russo C; Devun F; Al Abo M; Noguiez-Hellin P; Sun JS; Barillot E; Zinovyev A; Kuperstein I; Pommier Y; Dutreix M Clin Cancer Res; 2017 Feb; 23(4):1001-1011. PubMed ID: 27559053 [No Abstract] [Full Text] [Related]
50. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts. Laird J; Lok BH; Carney B; Kossatz S; de Stanchina E; Reiner T; Poirier JT; Rudin CM J Thorac Oncol; 2019 Oct; 14(10):1743-1752. PubMed ID: 31195178 [TBL] [Abstract][Full Text] [Related]
51. Targeting cancer stem cells in the tumor microenvironment: An emerging role of PARP inhibitors. Paul S; Sinha S; Kundu CN Pharmacol Res; 2022 Oct; 184():106425. PubMed ID: 36075511 [TBL] [Abstract][Full Text] [Related]
52. Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage. Giovannini S; Weller MC; Repmann S; Moch H; Jiricny J Nucleic Acids Res; 2019 Sep; 47(17):9132-9143. PubMed ID: 31329989 [TBL] [Abstract][Full Text] [Related]
53. Targeting cervical cancer: Is there a role for poly (ADP-ribose) polymerase inhibition? Tomao F; Santangelo G; Musacchio L; Di Donato V; Fischetti M; Giancotti A; Perniola G; Petrella MC; Monti M; Palaia I; Muzii L; Benedetti Panici P J Cell Physiol; 2020 Jun; 235(6):5050-5058. PubMed ID: 31912897 [TBL] [Abstract][Full Text] [Related]
54. PARP Inhibitor Inhibits the Vasculogenic Mimicry through a NF-κB-PTX3 Axis Signaling in Breast Cancer Cells. Chivot J; Ferrand N; Fert A; Van Dreden P; Morichon R; Sabbah M Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555812 [TBL] [Abstract][Full Text] [Related]
55. PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review. Mehta P; Bothra SJ Adv Genet; 2021; 108():35-80. PubMed ID: 34844716 [TBL] [Abstract][Full Text] [Related]